ArticleThe American journal of surgical pathology2017
A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Article in The American journal of surgical pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 106 citations in OpenAlex.
- FUS/EWSR1::TFCP2-rearranged bone and soft tissue tumors: evidence of gene promiscuity.Virchows Archiv : an international journal of pathology · 2026Article
- Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival.JCO precision oncology · 2026Article
- Rare intracranial mesenchymal tumors with FET::CREB fusions: clinicopathologic spectrum of four cases with integrated molecular analysis and review of the literature.Brain tumor pathology · 2026Article
- Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.Frontiers in oncology · 2026Article
- The genetics of cancer heterogeneity and mesothelioma.Frontiers in oncology · 2026Review
- Immunohistochemical evaluation of CREM in CREB-rearranged mesenchymal tumors and their mimics.Virchows Archiv : an international journal of pathology · 2025Article
- Malignant epithelioid tumors with EWSR1::CREB fusion involving the kidney: a report of two cases.Virchows Archiv : an international journal of pathology · 2025Article
- Durable Response to Pazopanib (Tyrosine Kinase Inhibitor) in a Patient With EWSR1::CREM Gene Fusion Positive Intra-Abdominal Unclassified Epithelioid Sarcoma.Genes, chromosomes & cancer · 2025Review
- EWSR1::CREM rearranged intra-abdominal malignant epithelioid neoplasm: two new cases of an emerging entity with clinicopathological characteristics and histological pitfalls.Virchows Archiv : an international journal of pathology · 2025Article
- Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib.Frontiers in oncology · 2025Article
- EWSR1::ATF1 fusions characterize a group of extra-abdominal epithelioid and round cell mesenchymal neoplasms, phenotypically overlapping with sclerosing epithelioid fibrosarcomas, and intra-abdominal FET::CREB fusion neoplasms.Virchows Archiv : an international journal of pathology · 2024Article
- Loss of clear cell characteristics in aggressive clear cell odontogenic carcinoma: a case report.Diagnostic pathology · 2024Article
- Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges.Frontiers in cell and developmental biology · 2024Article
- Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.Current oncology reports · 2023Review
- Modeling sarcoma relevant translocations using CRISPR-Cas9 in human embryonic stem derived mesenchymal precursors.Genes, chromosomes & cancer · 2023Review
- CREB fusion-associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype.Virchows Archiv : an international journal of pathology · 2023Article
- The oncogenic properties of the EWSR1::CREM fusion gene are associated with polyamine metabolism.Scientific reports · 2023Article
- Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022Review
- The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.Current oncology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Malignant mesothelioma (MM) is a rare, aggressive tumor often associated with asbestos exposure and characterized by complex genetic abnormalities, including deletions of chromosome 22. A gene fusion involving EWSR1 and YY1 gene on 14q32 has been reported in 2 patients over the age of 60 with peritoneal MM. However, the incidence of EWSR1 rearrangements in MM and the spectrum of its fusion partners remain unknown. We recently encountered 2 MM cases with EWSR1-ATF1 fusions and sought to investigate the prevalence and clinicopathologic features associated with this abnormality. As both index cases occurred as intra-abdominal tumors in young adults, we searched our files for pleural and peritoneal MM occurring in adults younger than age of 40. All cases were tested by fluorescence in situ hybridization using custom bacterial artificial chromosomes probes for EWSR1, FUS, and ATF1 genes. When available, immunohistochemistry for BAP1 was performed. A total of 25 MM from patients aged 40 or less were screened, either from peritoneum (n=13) or pleura (n=12), with a median age of 31 (range: 7 to 40 y). Two additional ATF1-rearranged tumors were identified at pleural and peritoneal sites with EWSR1 and FUS as fusion partners, respectively, for a total of 4 cases (16%, 4/25). The fusion-positive cases displayed classic epithelioid morphology, immunoreactivity for cytokeratins and WT1, and negativity for S100. BAP1 expression was retained in the 3 fusion-positive cases with available material, and in 80% (12/15) of the fusion-negative cases. Our results expand the spectrum of tumor types harboring EWSR1/FUS-ATF1 gene fusions to include a subgroup of conventional epithelioid MM. Other features of this unique MM subset include young age at presentation, lack of asbestos exposure and retained BAP1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.